We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
10.50 | 11.50 | 11.125 | 11.00 | 11.00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | -5.86M | -0.0063 | -17.46 | 102.06M |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
16:01:32 | O | 1,000 | 11.00 | GBX |
Date | Time | Source | Headline |
---|---|---|---|
09/12/2024 | 11:41 | UK RNS | Scancell Holdings Plc Result of Retail Offer and Total Voting Rights |
06/12/2024 | 12:11 | ALNC | IN BRIEF: Scancell funded deep into 2026 as raises GBP10 million |
05/12/2024 | 12:39 | UK RNS | Scancell Holdings Plc Result of Placing and Subscription |
04/12/2024 | 18:03 | UK RNS | Scancell Holdings Plc Retail Offer for up to £1 million |
04/12/2024 | 17:59 | UK RNS | Scancell Holdings Plc Proposed fundraise in excess of £8.5 million |
04/12/2024 | 07:00 | UK RNS | Scancell Holdings Plc Second Commercial License Agreement with Genmab |
18/11/2024 | 15:55 | ALNC | Scancell announces promising findings from cancer drug trial |
18/11/2024 | 07:00 | UK RNS | Scancell Holdings Plc Positive data from Phase 2 SCOPE trial with SCIB1 |
26/10/2024 | 12:48 | ALNC | EXECUTIVE CHANGES: New Scancell, Nanoco and LPA CEOs; Coral CEO exits |
25/10/2024 | 14:26 | UK RNS | Scancell Holdings Plc Result of Annual General Meeting |
Scancell (SCLP) Share Charts1 Year Scancell Chart |
|
1 Month Scancell Chart |
Intraday Scancell Chart |
Date | Time | Title | Posts |
---|---|---|---|
21/12/2024 | 10:20 | Scancell - Pot of Gold or POS? | 15,551 |
12/12/2024 | 12:42 | Scancell investors thread (litter free) | 578 |
06/12/2024 | 11:01 | Using immunology to fight cancer. | 57,674 |
14/6/2024 | 11:23 | Scancell for investors (inanaco free thread) | 237 |
01/12/2023 | 15:26 | Scancell - BS free thread | 2 |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|
Top Posts |
---|
Posted at 21/12/2024 08:20 by Scancell Daily Update Scancell Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SCLP. The last closing price for Scancell was 11p.Scancell currently has 927,819,977 shares in issue. The market capitalisation of Scancell is £102,060,197. Scancell has a price to earnings ratio (PE ratio) of -17.46. This morning SCLP shares opened at 11p |
Posted at 20/12/2024 07:32 by chilltime Apologies if anyone is in Synairgen, but it's an excellent example today of the typical fund raise destruction that has been going on for a year or two.The typical 2 week rule (fund raise roadshow) can be seen in the drop of the share price. In other words leaky and the market dropping the price forward selling. In short it was about 5p 2 weeks ago, 3.75p yesterday, a 25% drop and now a discount down to 2p a 60% drop on 2 weeks ago. But the real killer is the shares in issue. From about 200m in issue yesterday to 1.1 billion in issue now a dilution of 5.5 fold. Log that’s what I was on about, Scancell raise in comparison to the recent market circs is a non event. That’s the reality of it. Which shows the support and belief in Scancell’s science. Scancell was just a 10% dilution, but I don’t fully understand the timing there on the back of a known supply (estate and Calculus) holding the share price down. A question for the next AGM on business nous perhaps. |
Posted at 19/12/2024 16:56 by ruckrover Inan,"Can you leave out the anomaly of the share price movements ruck ? your good at that"Yes, if there is abnormal data I will leave it out as statistically that is the correct thing to do. (I realise you won't understand this with your skimpy stats knowledge). Although tbf I haven't spotted any obvious anomalies is the daily share price data set."you could correlate the amount of posting 2tyke has done here, with the natural variation of winter storms ... which seam higher than normal."Not sure what seam higher is, is it when you turn up your trousers?"can you predict if he is Off his Meds. or On ?"As you are probably on the same meds, you are possibly in a better position to tell than me. That's so long as you are ON your meds atm. |
Posted at 19/12/2024 15:45 by marcusl2 Redmile and Vulpes will not let Scancell go cheaply.Jonathan Prynn Thu 19 December 2024 at 10:22 am GMT 2 min read Companies snapped up this year include Loungers, which agreed a £338m bid from a US investment firm (Loungers) Companies snapped up this year include Loungers, which agreed a £338m bid from a US investment firm (Loungers) The City is set to come under siege from a “major and sustained” flow of takeovers of London listed companies next year that could see up to a third of small and mid-cap AIM businesses vulnerable to bids, an investment bank warned today. Peel Hunt predicted that the trend of London listed companies being “taken out” by private equity or foreign based corporate raiders will accelerate in the New Year “absent an unexpected change in circumstances.&rdquo The deluge of companies leaving the public arena is seen as a growing threat to London’s status as a pre-eminent global financial centre. A total of 88 companies delisted or transferred their primary listing from London’s main market this year, the highest since the financial crisis, with only 18 taking their place, according to the London Stock Exchange Group. Michael Nicholson, head of advisory & M&A at Peel Hunt wrote in a report titled “Barbarians at the Gate”: “We observe a wave of demand approaching the shores of the UK – with strategic and private equity buyers simultaneously active – and our coastal defences feel weaker than ever.” The report states that up to a third of small and mid-cap AIM businesses are vulnerable to acquisition due to a lack of liquidity, depressed valuations and “reduced ability to utilise the capital markets.” Nicholson went on: “Approaches to UK listed companies are now coming at an increased rate with those that become public knowledge far outweighed by those that are yet to (or may never) see the light of day. We see this trend only accelerating in the new year, absent an unexpected change in circumstances. Over 2024, 1 in 20 of all UK listed companies have been put under offer publicly - the highest level we have observed in recent years. “In addition to unsolicited approaches from potential bidders, we hear increasingly from UK boards who are seeking to explore their strategic options and assess the feasibility of a sale process. “The option to run a private sale process under revised Takeover Code rules has made this a more palatable option for many boards. For smaller companies, low share liquidity, a share price that barely responds to positive news (but overreacts to negative news), and a perceived structural dislocation of the share price from fundamental value all call into question the merits of being listed. “The exodus of capital from UK equity funds and the reduction of tax incentives to invest in AIM only serve to whip up the headwinds facing the UK small and mid-cap segment.” |
Posted at 17/12/2024 17:37 by 2tyke It won't help with stock prices.Economics is about business production, consumption and distribution. Profits and loss. If stock prices followed these principles they would be easy to predict. Anyone numerate could get a ball park Price. But they can't. Look at broker economic assessment of SP's. Are they in any way meaningful with say SCLP? Anymore than yours moonparty ...lol I'll give you a clue ..the answer is NO. In actual fact...some stocks with no revenues have sky high multiples....and some stocks that are very profitable have very low share price multiples. Economics is NOT the driver with asset prices. Investor psychology is the driver. |
Posted at 13/12/2024 12:01 by ivyspivey Morning All,Back home after a very nice Xmas Do in the Home Counties. As others have said why is it the ones so emotionally attached get so wound up about anyone questioning their investment or commenting on the share price which is entirely predictable. Before anyone thinks I am trying to get the share price down which is a nonsense as none of us influences that and anyway filled up nicely at the placing price as I do think this is an attractive proposition from current levels. Just don’t fall for the unlimited expectations of some who pontificate on here unless you want to set yourselves up for disappointment again imo. |
Posted at 26/11/2024 19:43 by 2tyke Oh you think a healthy 7% correction constitutes a crashing ponzi-scheme do you inane ?Why not compare your investment prowess against mine over the past 12 years we've held these choices............. Bitcoin up 7500 % ( only ever 21 million) SCLP down 78%.... including massive dilution. Hmmm ...makes you look a bit of an investment idiot doesn't it ? Well..we knew you were that anyway ! .................... And actually if you care to look on NASDAQ. There are a few companies in the same therapeutic area as scancell and at the same trial stage. Difference is the NASDAQ companies are a fraction of the SCLP share price |
Posted at 24/11/2024 22:19 by gazza "Price moves SELDOM have anything to do with Scancell"Very true. I remember at an AGM someone asking a question about the share price. John Chiplin (the chairman at the time) was quite abrupt in his answer: "we have absolutely no control over the share price".Nothing Scancell does affects this. All they can do is create a company and situation where the company is worth, according to TD, 33p. What the shares change hands at is all down to what someone is willing to sell at and someone is willing to buy for. If you understand this, you can formulate an investment strategy that takes advantage of any anomalies. Clue: it's not buy and hold! |
Posted at 23/11/2024 16:35 by inanaco Dom has been doing that for years MT ... makes a sarky remark then pops out for a coffee to reappear 6 months later because he is depressed about the share price bit like moljensadly your exhibitions don't help either no science posts and most of the post you do make are worthless example ……so at least 7 years from the lead investor coming in to take-off point for the share price (triggered, for Tesla, by a JD Power analysis). Count back from today to when Vulpes and Redmile came on board Scancell. We are now getting close, IMO, to the “JD Power moment” when someone influential will highlight the potential of Lindy’s approach. who are you expecting Jeremy Clarkson ? what a pile of nonsense ............ we have influencers already ... Genmab and the advisory panel that have joined Scancell you may get recs from the thicko's on here but what are they worth to you? nothing whats counts is how many shares you have when the event occurs and that is all there is to this share except .... its now moved to the middle of next year no problem for me another batch gets locked into ISA like i said the share price not moving is advantageous to buyers ... |
Posted at 18/11/2024 18:22 by gazza "serious question What will stop the share price rise ???"What share price rise? My screen shows a 5.5% fall. Did you mean to ask "what will stop the share price FALL?" Well, it doesn't seem that good news prevents a fall. However, what some fail to realise is that it's NOT all about the science. Burble, who probably knows more about the science than all of us put together, knows this and can comment sensible on financials. As Inan doesn't understand, he has to resort to calling it "gibberish". So the only thing that will stop the slide is clarity on funding. So do we need this NOW. Technically no, but the sooner this unknown is removed, the sooner the share price can find a sensible level. So you have to decide: Are you on the reality railway or the looney lunar rocket? |
Posted at 18/11/2024 18:11 by miavoce Shame is that based on the quality of these results the share price really should have gone up strongly today - these results wipe the floor with existing treatments. So why didn't the share price go up ? IMO this was because of combination of the following.1. Somebody is still dumping large blocks of shares - Calculus ? Who knows. Held the price back. 2. Punters incorrectly took the lack of a rise as a signal that the result weren't all that great and either sold or didn't buy. 3. The market doesn't understand how good these results really are. 4. The ORR fell short of the earlier 85% and this was taken as a negative despite the fact that the ORR achieved is 50% better than the current best (72% vs. 48%) Bottom line is that these shares are fantastic value at the current price with SCIB1 now further de-risked and showing massive potential (and surely of interest to a partner). The snippets of new info on Modi1 shared in the interview were also very positive. I believe that once the market has digested today's news we will see the share price move north steadily. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions